These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6862842)

  • 21. The use of lisuride in severe Parkinson's disease.
    Chin D; Yu YL; Huang CY
    Clin Exp Neurol; 1986; 22():63-9. PubMed ID: 3581512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low dose lisuride in advanced Parkinson disease.
    Degl'Innocenti F; Ginanneschi A; Magnolfi S; Catarzi L; Marini P
    Ital J Neurol Sci; 1987 Aug; 8(4):351-5. PubMed ID: 3679785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lisuride and pergolide in Parkinson's disease.
    Lang AE; Sheehy MP; Quinn NP; Brincat S; Marsden CD; Parkes D
    Adv Neurol; 1983; 37():109-20. PubMed ID: 6858769
    [No Abstract]   [Full Text] [Related]  

  • 24. Parenteral administration of lisuride in Parkinson's disease.
    Luquin MR; Obeso JA; Martínez-Lage JM; Tresguerres J; Parada J; Nieuweboer B; Dorow R; Horowski R
    Adv Neurol; 1987; 45():561-8. PubMed ID: 3825733
    [No Abstract]   [Full Text] [Related]  

  • 25. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas.
    Liuzzi A; Dallabonzana D; Oppizzi G; Verde GG; Cozzi R; Chiodini P; Luccarelli G
    N Engl J Med; 1985 Sep; 313(11):656-9. PubMed ID: 4022058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of lisuride in advanced Parkinson's disease. Potent dopamine and serotonin agonist.
    Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Goodgold A; Pact V; Walker R
    N Y State J Med; 1981 Nov; 81(12):1751-5. PubMed ID: 6949052
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-term treatment of acromegaly with lisuride: differences of effect on growth hormone and somatomedin.
    Marek J; Srámková J; Schüllerová M; Stĕpán J; Schreiberová O
    Endokrinologie; 1981 Dec; 78(2-3):175-85. PubMed ID: 7037372
    [No Abstract]   [Full Text] [Related]  

  • 28. Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa.
    Lieberman A; Goldstein M; Neophytides A; Kupersmith M; Leibowitz M; Zasorin N; Walker R; Kleinberg D
    Neurology; 1981 Aug; 31(8):961-5. PubMed ID: 7022259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of efficacy of lisuride hydrogen maleate with increased doses of levodopa in parkinsonian patients.
    Rabey JM; Treves T; Streifler M; Korczyn AD
    Adv Neurol; 1987; 45():569-72. PubMed ID: 3825734
    [No Abstract]   [Full Text] [Related]  

  • 30. Intravenous lisuride infusion for Parkinson's disease.
    Obeso JA; Martinez-Lage JM; Luquin MR; Bolio N
    Ann Neurol; 1983 Aug; 14(2):252. PubMed ID: 6625541
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline, and lisuride.
    Crosignani PG; Ferrari C; Liuzzi A; Benco R; Mattei A; Rampini P; Dellabonzana D; Scarduelli C; Spelta B
    Fertil Steril; 1982 Jan; 37(1):61-7. PubMed ID: 7199483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pergolide and lisuride for Parkinson's disease.
    Lieberman AN; Leibowitz M; Neophytides A; Kupersmith M; Mehl S; Kleinberg D; Serby M; Goldstein M
    Lancet; 1979 Nov; 2(8152):1129-30. PubMed ID: 91856
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of ergot derivative lisuride in Parkinson's disease.
    Suchy I; Horowski R
    Adv Neurol; 1984; 40():515-21. PubMed ID: 6695629
    [No Abstract]   [Full Text] [Related]  

  • 34. Pergolide and lisuride for levodopa-induced oscillations.
    Lees AJ; Stern GM
    Lancet; 1981 Sep; 2(8246):577. PubMed ID: 6116014
    [No Abstract]   [Full Text] [Related]  

  • 35. Animal model of depression: imipramine, bromocriptine and lisuride alleviate motor depression.
    Golda V; Petr R; Rozsíval V; Suba P
    Act Nerv Super (Praha); 1986 Mar; 28(1):26-7. PubMed ID: 3727904
    [No Abstract]   [Full Text] [Related]  

  • 36. Pergolide and lisuride in advanced Parkinson's disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Goldstein M
    Adv Neurol; 1984; 40():503-7. PubMed ID: 6695627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth hormone and changes in the secretion of thyrotropic hormone after thyrotropin-releasing hormone (TRH): ineffectiveness of dopaminergic stimulation.
    Felt V; Nedvídková J
    Endokrinologie; 1982 Oct; 80(2):201-6. PubMed ID: 6819130
    [No Abstract]   [Full Text] [Related]  

  • 38. Lisuride in Parkinson's disease. 4-year follow-up.
    Giovannini P; Scigliano G; Piccolo I; Soliveri P; Suchy I; Caraceni T
    Clin Neuropharmacol; 1988 Jun; 11(3):201-11. PubMed ID: 3401856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of pergolide and bromocriptine therapy in parkinsonism.
    LeWitt PA; Ward CD; Larsen TA; Raphaelson MI; Newman RP; Foster N; Dambrosia JM; Calne DB
    Neurology; 1983 Aug; 33(8):1009-14. PubMed ID: 6348585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Size reduction of macroprolactinomas by bromocriptine or lisuride treatment.
    Chiodini P; Liuzzi A; Cozzi R; Verde G; Oppizzi G; Dallabonzana D; Spelta B; Silvestrini F; Borghi G; Luccarelli G; Rainer E; Horowski R
    J Clin Endocrinol Metab; 1981 Oct; 53(4):737-43. PubMed ID: 7287863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.